Asthma and lower airway diseaseClinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program
Section snippets
Study population
CAMP was a multicenter, randomized, double-blind, placebo-controlled trial established to investigate the long-term effects of commonly prescribed asthma treatment regimens. In total, 1041 children were randomized to receive inhaled budesonide, inhaled nedocromil, or placebo. Participants were subsequently followed for a mean of 4.3 years with lung function studies and questionnaires at regular intervals. Phenotypic characteristics including lung function parameters, IgE levels, peripheral
Results
Observational data from CAMP nicely illustrate the heterogeneous nature of the response to inhaled β2-adrenergic agonists in children with mild-to-moderate persistent asthma. The distribution of response to bronchodilators at randomization is shown in Fig 1. The distributions of BDRs at each of the yearly follow-up visits were similar to that shown. As expected, the vast majority of children in the CAMP demonstrated a variable response to inhaled β2-adrenergic agonists at each of their yearly
Discussion
Before this study, there had been little research into the clinical predictors of consistent response to inhaled β2-adrenergic agonists or the clinical outcomes associated with this asthma phenotype. With more than 1000 patients with repeated measures of BDRs and a notable variability in response to bronchodilators, CAMP is a good cohort in which to study the consistent BDR phenotype. Based on the current analysis, it is clear that certain clinical parameters are associated with consistency in
References (24)
- et al.
The global burden of asthma: executive summary of the GINA Dissemination Committee report
Allergy
(2004) - et al.
GINA guidelines on asthma and beyond
Allergy
(2007) - et al.
Adverse effects of beta-agonists: are they clinically relevant?
Am J Respir Med
(2003) - et al.
Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction
Am Rev Respir Dis
(1986) - et al.
Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma
J Allergy Clin Immunol
(2006) - et al.
Interrupter resistance short-term repeatability and bronchodilator response in preschool children
Respir Med
(2007) - et al.
The pharmacogenetics of asthma: an update
Curr Opin Mol Ther
(2005) - et al.
Familial aggregation of bronchodilator response: a community-based study
Am J Respir Crit Care Med
(2002) The Childhood Asthma Management Program (CAMP): design, rationale, and methods
Control Clin Trials
(1999)Long-term effects of budesonide or nedocromil in children with asthma
N Engl J Med
(2000)
Interpretative strategies for lung function tests
Eur Respir J
The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables
Am Rev Respir Dis
Cited by (65)
Sensitivity of FEV<inf>1</inf> and Clinical Parameters in Children With a Suspected Asthma Diagnosis
2023, Journal of Allergy and Clinical Immunology: In PracticeBronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations
2020, Journal of Allergy and Clinical Immunology: In PracticeObstruction phenotype as a predictor of asthma severity and instability in children
2018, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The cut point of a 10% predicted change in FVC was selected arbitrarily, lacking published guidelines for a minimally important change for this variable. However, a 10% change in FEV1 with bronchodilation in children has diagnostic specificity for asthma15 and an association with asthma instability16 in children. Because FEV1 changes proportionally with changes in FVC,5 our cut point for a change in FVC should be meaningful.
The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma
2018, Annals of Allergy, Asthma and ImmunologyAssociation of FEF<inf>25%–75%</inf> and bronchodilator reversibility with asthma control and asthma morbidity in inner-city children with asthma
2016, Annals of Allergy, Asthma and Immunology
The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. Additional support for this study was provided by grants U01 HL075419, U01 HL65899, P01 HL083069, and T32 HL07427 from the National Heart, Lung, and Blood Institute, National Institutes of Health.
Disclosure of potential conflict of interest: A. L. Fuhlbrigge has served on the speakers' bureau and respiratory specialist advisory panel for GlaxoSmithKline and Merck, has received funding from Novartis and Sepracor, and has received research grants from Boehringer Ingelheim, GlaxoSmithKline, and Merck. S. J. Szefler has served as a consultant for AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and has received research grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); the Childhood Asthma Management Program; NHLBI Childhood Asthma Research and Education; the NIH/NHLBI Asthma Clinical Research Network; the NIH/National Institute of Allergy and Infectious Diseases Inner-City Asthma Consortium; and Ross Pharmaceuticals. R. S. Zeiger has served as a consultant for AstraZeneca, Aerocrine, Merck, Schering-Plough, Genentech, Dynavac, and GlaxoSmithKline and has received research grant from Sanofi-Aventis, GlaxoSmithKline, Genentech and the NHLBI. S. T. Weiss has received research support from the NIH and Genentech. The rest of the authors have declared that they have no conflict of interest.
- ∗
The members of the research group are listed at the end of the article.